Claims for Patent: 10,085,992

Summary for Patent: 10,085,992

Title:	Transient protection of normal cells during chemotherapy
Abstract:	This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Inventor(s):	Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Apex, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC)
Assignee:	G1 Therapeutics, Inc. (Research Triangle Park, NC)
Application Number:	15/342,990
Patent Claims:	1. A method of reducing the effect of chemotherapy on healthy cells in a human treated for cyclin-dependent kinase 4/6 (CDK4/6) replication independent small cell lung cancer, wherein said healthy cells are hematopoietic stem cells or hematopoietic progenitor cells, the method comprising administering to the human an effective amount of chemotherapeutic agent carboplatin, an effective amount of chemotherapeutic agent etoposide, and an effective amount of a CDK4/6 inhibitor of the formula: ##STR00330## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the CDK4/6 inhibitor is administered to the human prior to administration of carboplatin and etoposide. 3. The method of claim 2, wherein the CDK4/6 inhibitor is administered to the human about 4 hours or less prior to administration of carboplatin and etoposide. 4. A method of reducing the effect of chemotherapy on healthy cells in a human treated for cyclin-dependent kinase 4/6 (CDK4/6) replication independent small cell lung cancer, wherein said healthy cells are hematopoietic stem cells or hematopoietic progenitor cells, wherein the chemotherapy is administered during a 21-day chemotherapeutic treatment cycle, the method comprising: administering to the human on day 1 of the 21-day chemotherapeutic treatment cycle an effective amount of chemotherapeutic agent carboplatin, an effective amount of chemotherapeutic agent etoposide, and an effective amount of a CDK4/6 inhibitor of the formula: ##STR00331## or a pharmaceutically acceptable salt thereof, wherein the CDK4/6 inhibitor is administered prior to the administration of carboplatin and etoposide; and administering to the human on day 2 and day 3 of the 21-day chemotherapeutic treatment cycle an effective amount of the chemotherapeutic agent etoposide and an effective amount of the CDK4/6 inhibitor, or a pharmaceutically acceptable salt thereof, wherein the CDK4/6 inhibitor is administered prior to administration of etoposide. 5. The method of claim 4, wherein the CDK4/6 inhibitor is administered to the human about 4 hours or less prior to administration of carboplatin and etoposide on day 1 of the 21-day chemotherapeutic treatment cycle. 6. The method of claim 4, wherein the CDK4/6 inhibitor is administered to the human about 4 hours or less prior to administration of etoposide on day 2 and day 3 of the 21-day chemotherapeutic treatment cycle. 7. The method of claim 3, wherein the CDK4/6 inhibitor is administered about 30 minutes or less prior to administration of carboplatin and etoposide. 8. The method of claim 5, wherein the CDK4/6 inhibitor is administered about 30 minutes or less prior to carboplatin and etoposide. 9. The method of claim 6, wherein the CDK4/6 inhibitor is administered 30 minutes or less prior to etoposide.